A roundtable discussion on screening, managing and educating patients on Fuchs’ dystrophy in community optometry ...

Design Therapeutics Inc. has described transcription modulators reported to be useful for the treatment of myotonic dystrophy type 1 (DM1) and Fuchs’ dystrophy.

CARLSBAD, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, ...

The global Fuchs Endothelial Corneal Dystrophy (FECD) market is experiencing robust growth, driven by advancements in corneal transplantation techniques, increased awareness of rare ocular diseases, ...

New national research led by Jonathan Lass of Case Western Reserve University School of Medicine has found that corneal donor tissue can be safely stored for 11 days before transplantation surgery to ...